Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Tizona Therapeutics
601 Gateway Blvd., Suite 350
South San Francisco, CA 94080

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks 'self' tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Tizona's lead drug candidate, an anti-CCR4 monoclonal antibody, is expected to enter the clinic in 2017

Key Contact
Name
Pablo J. Cagnoni, M.D.
Title
President and CEO
Funding Events

Date
Amount
Type
Investors
Valuation
03/08/16 $43,000,000 Series B Abingworth
Amgen Business Development
Astellas Venture Management
Canaan Partners
InterWest Partners
Lightstone Ventures
MPM Capital
undisclosed


Featured Reading